New strategies are needed in diffuse malignant mesothelioma

• Published in: Cancer 1992-12, Vol.70 (12), p.2969-2979
• Main Authors: Sridhar, Kasi S., Doria, Xaul, Raub, William A., Thurer, Richard J., Saldana, Mario
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological and medical sciences; doxorubicin; Female; Humans; Male; Medical sciences; mesothelioma; Mesothelioma - drug therapy; Mesothelioma - mortality; Mesothelioma - therapy; metachronous cancers; Middle Aged; Multicenter Studies as Topic; multitechnique therapy; pirarubicin; Pneumology; primary chem otherapy; prochlorperazine; Prognosis; Tumors of the respiratory system and mediastinum
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/1097-0142(19921215)70:12<2969::AID-CNCR2820701239>3.0.CO;2-A

Background. Medical records of 50 patients with malignant mesothelioma were reviewed to determine the clinical features and factors influencing survival. Methods. Charts of all patients whose conditions were diagnosed as malignant mesothelioma were ed and analyzed by statistical software. Results. The male‐to‐female ratio was 4:l. The age distribution was younger than 45 years of age, 10%; 45–54 years of age, 12%; 55–64 years of age, 37%; 65–74 years of age, 33%; and 75 years of age or older, 8%. Both mean and median ages were 58 years. Among the 32 patients in whom asbestos exposure was recorded, 24 had documented exposure. The sites were pleura, 73%; peritoneum, 20%; and both, 6%. The histologic types were epithelial, 51%; sarcomatous, 10%; mixed, 15%; and not specified, 24%. The stage at presentation was Stage I, 37%; 11, 39%; 111, 12%; IV, 6%; and unknown, 6%. The common symptoms in pleural disease were dyspnea and pain; in peritoneal disease, abdominal distension and pain were common. The median time from first symptom to diagnosis was 3 months (range, 0–23 months). The median survival after the appearance of symptoms, the diagnosis, and the treatment were 13,10, and 8 months, respectively. Conclusions. The survival was independent of age, sex, and smoking behavior. It was longer in patients with earlier‐stage disease, a good performance status, a longer duration of symptoms, an absence of pain, and who were treated with combined surgery and chemotherapy. Chemotherapy using anthracyclines yielded more remissions (9 of 21) than that using nonanthracyclines (0 of 13). The remission rate after primary chemotherapy with anthracyclines (7 of 16) may be higher than in recurrent tumor (2 of 14). In future trials, stratifization into primary chemotherapy and chemotherapy of recurrent cancer is suggested. There is a need for multi technique trials incorporating primary Chemotherapy.